VEEV
Updated: 24/09/2026, 00:59:09
Veeva Systems Inc. is a leading provider of cloud-based software solutions, exclusively dedicated to the global life sciences industry. Its extensive operational presence spans across North America, Europe, the Asia Pacific region, the Middle East, Africa, and Latin America. The company's product portfolio is primarily structured around two major offerings. First, the Veeva Commercial Cloud delivers an integrated suite of software, data, and analytics tools designed to optimize commercial operations. This includes vital applications such as Veeva Customer Relationship Management (CRM) and its specialized Medical CRM, Veeva Closed Loop Marketing (CLM), sophisticated analytics via Veeva CRM MyInsights, approved email communication with Veeva CRM Approved Email, digital engagement tools like Veeva CRM Engage, commercial alignment through Veeva Align, event management capabilities with Veeva CRM Events Management, data warehousing solutions (Veeva Nitro), data services (Veeva OpenData, Veeva Link), master data management (Veeva Network), advanced analytical insights (Veeva Crossix, Veeva Data Cloud), and patient engagement platforms (MyVeeva for Patients). Secondly, Veeva Vault provides a robust collection of cloud-native enterprise content and data management applications. These applications are engineered to support both critical commercial functions—encompassing sales, marketing, and medical content and communications—and comprehensive research and development processes, including clinical trials, regulatory compliance, quality management, and patient safety. Beyond its software, Veeva offers a wide array of professional and support services. These range from strategic implementation and deployment planning, project management, and detailed requirements analysis to solution design and configuration. They also include system environment management and deployment, expert consulting for business process transformation related to Veeva solutions, technical guidance on data migration and systems integrations, comprehensive training programs, and ongoing managed services such as outsourced systems administration. Tracing its origins, the company was incorporated in 2007 as Verticals onDemand, Inc., and subsequently rebranded to Veeva Systems Inc. in April 2009. Its corporate headquarters are situated in Pleasanton, California.
No summaries found.
Reported and calculated KPIs plus operational exposure disclosed in the FY 2026 filing.
Revenue
$3.2B
FY 2026 · Reported
Net income
$0.9B
FY 2026 · Reported
Gross margin
75.5%
FY 2026 · Calculated
Free cash flow
N/A
FY — · Reported
R&D intensity
24.0%
FY 2026 · Calculated
Share repurchases
$0.2B
FY 2026 · Reported
Other offerings mentioned without separate sales
Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.
Map layer
Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.
Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.
Company overview
Leading provider of industry cloud solutions for the global life sciences industry; offerings span cloud software, data, and business consulting.
“Veeva is the leading provider of industry cloud solutions for the global life sciences industry. Our offerings span cloud software, data, and business consulting”
Public benefit corporation status
Delaware public benefit corporation (PBC).
“We are a Delaware public benefit corporation (“PBC”).”
Four major product categories
Four product categories: Veeva Development Cloud, Veeva Quality Cloud, Veeva Commercial Cloud, and Veeva Data Cloud.
“Our industry cloud solutions for the life sciences industry are grouped into four major product categories—Veeva Development Cloud, Veeva Quality Cloud, Veeva Commercial Cloud, and Veeva Data Cloud”
Financial reporting segments
Commercial Solutions and R&D and Quality Solutions for financial reporting.
““Commercial Solutions” revenues refer to revenues associated with our Veeva Commercial Cloud and Veeva Data Cloud solutions, and “R&D and Quality Solutions” revenues refer to revenues associated with our Veeva Development Cloud and Veeva Quality Cloud solutions.”
Expansion beyond life sciences
Certain R&D and Quality Solutions offered to industries outside life sciences, primarily in North America and Europe.
“We also offer certain of our R&D and Quality Solutions to industries outside the life sciences industry primarily in North America and Europe.”
Customer counts
1,552/1,477/1,432 total customers; 767/730/693 Commercial Solutions; 1,196/1,125/1,078 R&D and Quality Solutions as of FY2026/2025/2024 year-ends.
“As of January 31, 2026, 2025, and 2024, we served 1,552, 1,477, and 1,432 customers, respectively.”
Veeva Development Cloud
Clinical, regulatory, and safety application suites on Veeva Vault: Veeva Clinical Platform, EDC/CDB, eTMF, CTMS, RTSM, Veeva Safety, Veeva RIM.
“Veeva Development Cloud includes application suites for the clinical, regulatory, and safety functions of life sciences companies, all built on our Veeva Vault platform.”
Veeva Quality Cloud
Veeva QMS, Veeva Quality Docs, quality control lab solutions, and training solutions on the Veeva Vault platform.
“Veeva Quality Cloud unifies quality applications, processes, and partners across content management, training, quality assurance, and quality control lab solutions on the Veeva Vault platform.”
Veeva Commercial Cloud
Veeva Vault CRM Suite, Veeva Medical, Veeva PromoMats, Veeva Crossix.
“Veeva Commercial Cloud includes solutions for the sales, marketing, and medical affairs functions of a life sciences company”
Veeva AI
Veeva AI adds agentic artificial intelligence to the Veeva Vault platform with industry-specific AI Agents.
“Veeva AI adds agentic artificial intelligence (“AI”) to our proprietary Veeva Vault platform and deep, industry-specific agents for Veeva applications.”
Veeva Data Cloud
Data platform including Veeva OpenData (healthcare professional and organization reference data).
“Veeva Data Cloud is a modern data platform comprised of connected reference data, deep data, and transaction data.”
Total and subscription revenue history
Total revenues $3,195M/$2,747M/$2,364M and subscription revenues $2,684M/$2,285M/$1,902M for FY2026/2025/2024; net income $909M/$714M/$526M.
“For our fiscal years ended January 31, 2026, 2025, and 2024, our total revenues were $3,195 million, $2,747 million, and $2,364 million, respectively”
FY2026 revenue mix by solution category
FY2026: ~47%/53% of subscription revenues and 45%/55% of total revenues from Commercial Solutions and R&D and Quality Solutions, respectively.
“we derived approximately 47% and 53% of our subscription revenues and 45% and 55% of our total revenues from our Commercial Solutions and R&D and Quality Solutions, respectively”
Revenue composition by type FY2026
FY2026: subscription revenues 84% of total; professional services and other revenues 16%.
“subscription revenues constituted 84% of total revenues and professional services and other revenues constituted 16% of total revenues.”
Foreign currency exposure and hedging
FX exposure particularly to EUR, JPY, CAD, GBP, CNY; engages in foreign currency transaction hedging.
“particularly changes in the Euro, Japanese Yen, Canadian Dollar, Great British Pound Sterling, and Chinese Yuan”
Macroeconomic and geopolitical risk factors
Tariffs, inflation, FX fluctuations, interest rates, Russia-Ukraine war, Middle East conflict, and recession concerns may negatively impact business.
“Uncertain macroeconomic and geopolitical factors, including as a result of changes in trade policies and practices (including the imposition of additional tariffs or threats to impose additional tariffs), worldwide inflationary pressures, currency exchange fluctuations”
R&D and Quality Solutions growth expectation
R&D and Quality Solutions revenues expected to increase as a percentage of subscription and total revenues.
“Revenues associated with our R&D and Quality Solutions are expected to increase as a percentage of both subscription revenues and total revenues in the future.”
Financial position
Cash $1.42B, short-term investments $5.14B, total assets $8.98B, deferred revenue $1.49B as of January 31, 2026; auditor KPMG LLP.
“Cash and cash equivalents$1,421,233 $1,118,785 Short-term investments5,139,581 4,031,442”
Life sciences regulation and drug pricing
Drug pricing reforms (IRA), government agency funding/staffing changes, and Sunshine Act reporting requirements affect the life sciences industry and demand for Veeva solutions.
“such as the drug pricing reforms in the Inflation Reduction Act, which went into effect in August 2022”
Cybersecurity risk
Security breach risk involving sensitive clinical, regulatory, patient, and medical professional data; elevated cyberattack risk from geopolitical tensions.
“If our security measures are breached or compromised or unauthorized access to customer data is otherwise obtained, our solutions may be perceived as not being secure”
CRM transition competition risk
Intense competition, particularly in CRM market as customers transition from legacy CRM to Vault CRM.
“We face intense competition in markets in which we operate—particularly in the CRM market as we transition customers from our legacy CRM application to our Vault CRM application”
Life sciences industry funding and consolidation risks
Customer consolidation, funding environment changes, bankruptcies, and reduced sales-rep counts (digital channel shift) may reduce demand.
“certain life sciences companies have reduced the number of sales representatives they employ due to an increased preference for digitally-enabled sales channels, which negatively impacted sales of our solutions”
Workforce risk
Difficulty attracting and retaining highly skilled employees may increase expenses.
“Difficulty attracting and retaining highly skilled employees could adversely affect our business and efforts to attract and retain such employees may increase our expenses.”
Third-party computing infrastructure dependency
Reliance on third-party providers for computing infrastructure and secure network connectivity to deliver cloud solutions.
“We rely on third-party providers for computing infrastructure, secure network connectivity, and other technology-related services needed to deliver our cloud solutions”
Data privacy regulation risk
Complex U.S. and international data privacy and information security regulations may impose costs and reduce demand.
“including increasingly complex U.S. and international data privacy and information security regulations and measures specific to the life sciences industry, may impose additional costs for compliance”
Nearly all revenues come from life sciences industry customers (pharmaceutical, biotechnology, MedTech), making Veeva's results highly dependent on that industry's health and regulation.
“Nearly all of our revenues are generated by sales to customers in the life sciences industry”
Demand driven by life sciences companies' commercial, R&D, and quality operations needs; industry consolidation, funding environment, and bankruptcies of early-stage biotechs can reduce demand.
“A reduction in private funding or the ability to secure funding in public markets for early-stage life sciences companies has resulted in the past, and may result in the future, in reduced sales and adverse effects to our financial results.”
Delivery of cloud solutions depends on third-party computing infrastructure and secure network connectivity providers; disruptions could harm the business.
“We rely on third-party providers for computing infrastructure, secure network connectivity, and other technology-related services needed to deliver our cloud solutions”
Veeva AI embeds agentic AI across the Veeva Vault platform and applications as a strategic product capability.
“Veeva AI adds agentic artificial intelligence (“AI”) to our proprietary Veeva Vault platform and deep, industry-specific agents for Veeva applications.”
Drug pricing reforms and government funding/staffing changes for FDA, NIH, and Medicaid could reduce life sciences revenues and demand for Veeva products.
“Significant changes in drug pricing policy or regulation could result in lower revenues and profits for life sciences companies and reduced demand for our products.”
Legacy Veeva CRM and related applications are built on a Salesforce-provided platform, supported only until December 31, 2029, during customer migration to Vault CRM.
“Veeva CRM and some of its related applications are built on a platform provided by Salesforce, Inc. and will be supported until December 31, 2029.”
Intense competition particularly in the CRM market during transition from legacy Veeva CRM to Vault CRM; failure to compete effectively could lose customers.
“We face intense competition in markets in which we operate—particularly in the CRM market as we transition customers from our legacy CRM application to our Vault CRM application”
Complex and evolving U.S. and international data privacy and security regulations may impose compliance costs, reduce demand, and create liability.
“Changing laws, regulations, and enforcement priorities, including increasingly complex U.S. and international data privacy and information security regulations and measures specific to the life sciences industry, may impose additional costs for compliance”
Breach or perceived insecurity of solutions handling sensitive life sciences data could cause customer loss and liabilities; generative AI is increasing attack sophistication.
“threat actors are using these technologies to create sophisticated new attack methods that are increasingly automated, targeted, coordinated, and difficult to defend against.”
International agreements denominated in local currencies expose results to FX fluctuations, particularly EUR, JPY, CAD, GBP, CNY; hedging used but may not fully offset.
“our results of operations and cash flows are subject to fluctuations due to changes in foreign currency exchange rates, particularly changes in the Euro, Japanese Yen, Canadian Dollar, Great British Pound Sterling, and Chinese Yuan”
Tariffs on life sciences products or inputs could increase customer costs, reduce demand for their products, delay IT spending, and provoke retaliatory measures like digital services taxes.
“Tariffs imposed on the end products of the life sciences industry or on inputs relevant to the life sciences industry could increase costs for our customers or reduce demand for their products, which could delay or reduce their IT spending.”
Russia's invasion of Ukraine elevated cyberattack risk; significant life sciences customers scaled back operations and clinical trial activity in Russia, potentially reducing IT spending.
“a number of significant life sciences companies have scaled back sales, operations, and investments in Russia, including curtailing sales and marketing and clinical trial activity in Russia.”
See which prediction-market events move VEEV, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Veeva Systems Inc. (VEEV) is Attracting Investor Attention: Here is What You Should Know
Zacks Investment Research • STOCK • 11/06/2026, 12:00:28
Veeva's Falcon and Vault AI: When Could AI Become a Revenue Driver?
Zacks Investment Research • STOCK • 09/06/2026, 15:20:22
Here's Why Veeva Systems (VEEV) is a Strong Momentum Stock
Zacks Investment Research • STOCK • 09/06/2026, 12:51:06
UCB Unifies Global Pharmacovigilance Operations with Veeva Safety Suite
PRNewsWire • STOCK • 09/06/2026, 09:03:00
Veeva Systems Q1 Earnings Call Highlights AI Push & Higher Outlook
Zacks Investment Research • STOCK • 05/06/2026, 08:21:06
VEEV Stock Down Despite Q1 Earnings & Revenues Beat Estimates
Zacks Investment Research • STOCK • 04/06/2026, 17:00:25
Veeva Systems (NYSE: VEEV) Reports Strong Q1 Earnings and Strategic AI Shift
Market Data • Market Data • 04/06/2026, 07:00:20
Veeva Summit Previews Falcon and the Path to Agentic Biopharma
PRNewsWire • STOCK • 04/06/2026, 05:03:00
Veeva Systems Inc. (VEEV) Q1 2027 Earnings Call Transcript
Seeking Alpha • STOCK • 04/06/2026, 01:21:57
Here's What Key Metrics Tell Us About Veeva (VEEV) Q1 Earnings
Zacks Investment Research • STOCK • 03/06/2026, 20:31:05
Veeva Systems (VEEV) Q1 Earnings and Revenues Surpass Estimates
Zacks Investment Research • STOCK • 03/06/2026, 20:15:20
Veeva Announces Fiscal 2027 First Quarter Results
PRNewsWire • STOCK • 03/06/2026, 18:05:00
